The mTOR inhibitors everolimus and temsirolimus have already been approved for the treatment of metastatic renal cell carcinoma (temsirolimus, everolimus), mantle cell lymphoma (temsirolimus), breast cancer (everolimus), and pancreatic neuroendocrine tumors (everolimus) [4]. Here, MTOR is linked to breast carcinoma.